Sat, Dec 27, 2014, 8:06 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • thirdmeinvestor thirdmeinvestor Apr 27, 2013 8:52 PM Flag

    Match made in heaven -- DACLATASVIR and VX-135

    Gilead's sofosbuvir and Bristol’s daclatasvir [=BMS-790052] could make a happiest couple in the world if Gilead did allow sofosbuvir to wed daclatasvir. Read today's PR. But, Gilead said the dowry is too expensive and prefers a home-grown boy NS5A inhibitor. So, Bristol decided to screen VX-135 as a potential mate for daclatasvir. I have a hunch that VX-135 is as safe if not safer, and as potent, as sofosbuvir.

    There is a good reason to believe that inhibitors of NS5A and NS5B work together very well. A NS5A inhibitor is not just the disruptor of HCV replication complex. Just as protease inhibitors (like incivek) disrupt HCV's ability to evade host's immune response, NS5A inhibitors can also foil HCV's attempt to sabotage host's immunity, but in an independent pathway from protease inhibitors.

    Successes of all-oral HCV's non-structural protein inhibitors validate the concept that the currently developed DAAs have the immunological mechanism components, so that they can effectively replace interferon and ribavirin.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Ut oh ... looks like there is something out there that can cure the ones VRTX cant ... this cant be good news!!!

    • Also this; The combination had previously demonstrated success in patients who hadn’t been treated before. Those who have failed Incivek or Victrelis are “perhaps the most difficult-to-treat population” and have no current options, said Mark Sulkowski, a doctor at Johns Hopkins University in Baltimore who presented the results

    • You forgot to add this; Patients in both groups had failed prior treatment with either Vertex Pharmaceuticals Inc. (VRTX)’s Incivek or Merck & Co. (MRK)’s Victrelis

      Sentiment: Strong Sell

    • GILD never ran Phase II A or phase II B of 7977 and GS 5885 combo ( not that I know of) and went to Phase III to document safety after 200 patient data was available. Why VRTX can't do it? What are the risk that BMY will not let any company to run Phase III of Daclatasvir- Combo trial in future?

      Xeljanz Euorpean rejection is creating another opportunity to VRTX 509.

      VX 809/VX 770 has taken almost 2 months just to start.

      • 1 Reply to rojospan
      • Rojospan. We'll get a clearer read from Vertex management of how 809/770 enrollment is proceeding at the CC on Tues. The clinical website lists 110 international sites enrolling about 1000 patients. Not a small logistical feat for any pharma studying so many parameters in a very sick patient population. I suspect however enrollment will be complete before the end of June, given the time elapsed since announcement ot a registration path, and the high interest in CF patients for being in studies that could halt the progression of their otherwise terminal disease. Verity might be able to give us information from her perspective as to how quickly this study is being enrolled from the CF patient family's point of view.
        I hope we'll also get some information on Tuesday regarding the timing of initiation of clinical trials using VX 135 with GSK, JNJ, and BMY's compounds, in pan-genotypic populations of hepatitis C. Gilead will have maybe one year before serious competition in next generation all oral treatment of hep C evolves from Vertex and it's potential partners, with potentially greater efficacy in all genotypes and hard to treat subsets of hep C.
        Also, hope for news on Tuesday about the partnerships being negotiated using VX 509 for treatment of multiple autoimmune diseases, and VX 787 for treatment of both seasonal and pandemic strains of influenza. This latter drug as well as VX 509 has been largely ignored by analysts in their valuation of the Vertex pipeline, and any announced deal will give color to the potential revenue associated with each drug. Both compounds may have significant improvements for treating their respective patient populations over existing treaments in either efficacy and or tolerability. The ongoing evolution of mutaions of avian H7N9 influenza currently being monitored in China makes development of VX 787 particularly important if person to person transmission develops in this potentially deadly virus.

118.41+3.26(+2.83%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
Rice Energy Inc.
NYSEFri, Dec 26, 2014 4:02 PM EST
Westar Energy, Inc.
NYSEFri, Dec 26, 2014 4:07 PM EST